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RAS binding is a critical step in the activation of
BRAF protein serine/threonine kinase and stimula-
tion of themitogen-activated protein kinase signaling
pathway. Mutations in both RAS and BRAF are asso-
ciatedwithmany human cancers. Here, we report the
solution nuclear magnetic resonance (NMR) and
X-ray crystal structures of the RAS-binding domain
(RBD) from human BRAF. We further studied the
complex between BRAF RBD and the GppNHp
bound form of HRAS in solution. Backbone, side-
chain, and 19F NMR chemical shift perturbations
reveal unexpected changes distal to the RAS-bind-
ing face that extend through the core of the RBD
structure. Moreover, backbone amide hydrogen/
deuterium exchange NMR data demonstrate confor-
mational ensemble changes in the RBD core struc-
ture upon complex formation. These changes in
BRAF RBD reveal a basis for allosteric regulation of
BRAF structure and function, and suggest a mecha-
nism by which RAS binding can signal the drastic
domain rearrangements required for activation of
BRAF kinase.
INTRODUCTION
Intracellular signal transduction protein kinases play important
roles in transferring signals from the cell surface to the nucleus,
and are intimately involved in controlling numerous cellular
processes including cell growth, proliferation, and death. In hu-
mans, the protein kinase family is encoded by more than 500
genes, which can be subdivided, based on enzyme specificity,
into protein serine/threonine kinases, tyrosine kinases, and tyro-
sine kinase-like proteins (Manning et al., 2002). Serine/threonine
kinases are intracellular enzymes that include a small family of1382 Structure 23, 1382–1393, August 4, 2015 ª2015 Elsevier Ltd Alprotein kinases related to retroviral oncogenes discovered in
1983, named RAF (rapidly accelerated fibrosarcoma) (Lavoie
and Therrien, 2015; Matallanas et al., 2011; Roskoski, 2010).
The RAF kinase family comprises three known isoforms in
humans: ARAF, BRAF, and CRAF (also called RAF-1). RAF
kinases participate in the RAS-RAF-MEK-ERK signal transduc-
tion pathway, also called the mitogen-activated protein kinase
(MAPK) cascade. All three intracellular RAF kinases share highly
conserved regions (CR): CR1, CR2, and CR3. CR1 is composed
of a RAS-binding domain (RBD) immediately followed by a
cysteine-rich domain, which can bind two zinc ions. CR1 inter-
acts with RAS and membrane phospholipids. CR2 is a serine/
threonine-rich domain containing a 14-3-3 binding site, and
CR3 features the kinase domain.
RAF kinases exhibit high substrate selectivity, exclusively
targeting the dual-specificity (Tyr/Thr) kinases MEK1/2.
Regulation of RAF kinases is extremely complex and strictly
controlled by several factors and events, including protein-
protein interactions, phosphorylation/dephosphorylation at
numerous sites, and oligomerization state (Lavoie and Ther-
rien, 2015; Matallanas et al., 2011; Roskoski, 2010). For
example, RAF kinases are inhibited by binding of 14-3-3 and
autoinhibitory domains, which precludes dimerization of the
kinase domain and renders the enzyme inactive. Activation of
RAF kinases is triggered by RAS-GTP binding, phosphorylation
of the activation segment within the kinase, and conforma-
tional rearrangements involving both the aC helix and activa-
tion segment that lead to kinase domain dimerization required
for enzymatic activity (Lavoie et al., 2014; Thevakumaran et al.,
2015).
Mutations in the MAPK signaling pathway are associated with
numerous human cancers. In particular, RAS mutations occur in
z15% of all cancers, and mutations in BRAF, but not its
isoforms, are prevalent in melanomas (z66%), thyroid cancer
(up to 70%), ovarian cancer (z30%), colorectal cancer (up to
20%), and liver cancer (z14%) (El-Nassan, 2014). By far the
most common oncogenic mutation occurs in the activation
segment of BRAF, V600E, and is found in z90% of cancers
linked to this kinase. As a result, the kinase domain of BRAFl rights reserved
has been the focal point of extensive structural studies and inhib-
itor design, which has led to the development of two anticancer
drugs approved by the US Food and Drug Administration to
date, sorafenib and vemurafenib.
Although not sufficient on its own, the interaction of the two
oncoproteins RAS and BRAF is absolutely required for activation
of the MAPK pathway (Matallanas et al., 2011; Roskoski, 2010).
Consequently, understanding the nature of this interaction and
the mechanism by which RAS binding activates BRAF is biolog-
ically important. Several nuclear magnetic resonance (NMR) and
X-ray structures of RBD from CRAF, both free and in complex
with HRAS and its homologs, and an NMR structure of RBD
from ARAF have been reported. Initial structural and binding
studies of human (Emerson et al., 1995) and rat (Terada et al.,
1999) CRAF RBD by NMR established the interaction surface
for HRAS on the RBD, which was subsequently confirmed by
crystal structures of CRAF in complex with the RAS-like protein,
Rap1A (Nassar et al., 1995) and more recently with HRAS (Fetics
et al., 2015; Filchtinski et al., 2010). The reciprocal NMR studies
of effector binding to RAS and its oncogenic mutants, where
RAS is isotopically enriched, established a hierarchy of effector
binding to HRAS inwhich BRAFRBDdisplayed the highest-affin-
ity binding, and provide an elegant approach for directly moni-
toring the complex RAS signaling network (Smith and Ikura,
2014; Smith et al., 2013).
The RAS subfamily of guanine nucleotide-binding proteins
(G proteins), comprising three major isoforms in humans
(HRAS, KRAS, and NRAS), are small monomeric GTPases that
play a critical role in numerous signal transduction pathways
associated with cell growth and differentiation, andmany human
cancers (Stephen et al., 2014; Takai et al., 2001). RAS proteins
function as molecular switches, oscillating between inactive
GDP-bound and active GTP-bound states; the latter can bind
and activate a variety of effector proteins and signaling path-
ways. The populations of active and inactive forms of RAS are
tightly regulated by guanine nucleotide exchange factors
(GEFs), which catalyze GDP-to-GTP exchange, and GTPase-
activating proteins (GAPs), which lead to fast GTP hydrolysis
and regenerate the inactive GDP form of RAS. Since the initial
structural studies on RAS in the early 1990s, it has been well es-
tablished that RAS proteins adopt multiple conformational
states, and that such dynamics are largely associated with two
flexible surface loops intimately involvedwith nucleotide binding,
named switch I (residues 30–40) and switch II (residues 60–76)
(Kraulis et al., 1994; Milburn et al., 1990).
Although BRAF RBD shares 55%–60% sequence identity
with the corresponding domains in the ARAF and CRAF iso-
forms (Figure 1A), no structure for BRAF RBD has been reported
to date. Here, we report the first solution NMR and X-ray crystal
structures of RBD from the human protein serine/threonine ki-
nase BRAF (UniProtKB/Swiss-Prot: P15056; NESG: HR4694F).
BRAF RBD was selected for three-dimensional (3D) structure
determination by the Northeast Structural Genomics Con-
sortium (NESG; http://www.nesg.org) as part of the NIH Protein
Structure Initiative program on the Human Cancer Protein Inter-
action Network (HCPIN) (Huang et al., 2008). We further pre-
pared and characterized the complex of BRAF RBD and
HRAS loaded with a non-hydrolyzable analog of GTP, guano-
sine 50-[b,g-imido]triphosphate (GppNHp). Backbone chemicalStructure 23, 1382shift perturbations (CSPs) establish the RAS-binding epitope
on BRAF RBD. Moreover, backbone and side-chain CSPs, 19F
NMR, and hydrogen/deuterium exchange NMR data reveal allo-
steric conformational changes upon RAS binding, propagated
through the b sheet and a-helical core of the protein domain.
These changes in BRAF RBD that accompany RAS binding
provide a basis for allosteric regulation of BRAF structure and
function, and suggest a mechanism by which RAS binding
can signal domain rearrangements required for activation
of BRAF kinase. Furthermore, our results are consistent with
mounting evidence in the literature supporting the critical role
of conformational dynamics in macromolecular recognition
and allosteric regulation in biology.
RESULTS
Structure of BRAF RBD
The solution NMR structure ensemble and 2.0-A˚ resolution
crystal structure of BRAF RBD and structural statistics are pre-
sented in Figures 1B and 1C and Tables S1 and S2, respectively.
In solution, BRAFRBD is amonomer under the conditions used in
the NMR structure determination (pH 4.5 buffer), based on both
analytical gel filtration with static light-scattering detection (Fig-
ure S1) andmeasurements of its rotational correlation time deter-
mined from 15N T1 and T2 relaxation data (Figure S2). Essentially
complete backbone and side-chain resonance assignments
(Table S1) were obtained using conventional triple-resonance
NMR methods. These are reflected in its assigned 1H-15N heter-
onuclear single-quantum coherence (HSQC) spectrum (Fig-
ure S3), and summary of sequential backbone triple-resonance
connectivity and nuclear Overhauser effect spectroscopy
(NOESY) data (Figure S4). For the crystal structure, electron den-
sity was interpretable for 323 of 384 residues (including the 11
amino acid residues of the N-terminal affinity tag) from the four
protomers in the asymmetric unit, corresponding to residues
153–237 of BRAF. The first eight residues of the N-terminal tag
and final four C-terminal residues are flexible and not visible on
the electron density map. The final R factor of the atomic model
is 21.3%, and Rfree is 27.1% (Table S2).
The structure BRAF RBD adopts a classic ubiquitin a/b roll
composed of two a helices and a five-stranded mixed b sheet
(Figures 1B and 1C). Strands b1-b2 and b3-b4-b5 are antiparallel
to each other, while strands b1 and b5 are parallel. The two he-
lices, a1 helix after b2 strand and a2 310 helix after b4 strand,
pack against one face of the b sheet. The protein core, consisting
of residues 154–228, is well ordered except for residues 202–204
(in loop L4 between b3 and b4 strands) and the disordered N and
C termini. In general, core side-chain conformations are quite
well defined in the NMR ensemble (Figure S5). The average
backbone root-mean-square deviation (RMSD) between theme-
doid conformer of the NMR ensemble (the model with the lowest
average RMSD to all the other models in the ensemble) and each
conformer of NMR ensemble (0.75 ± 0.12 A˚, over residues
154–228) is comparable with the RMSD between the medoid
conformer and X-ray crystal structure (0.99 A˚). The BRAF RBD
solution and crystal structures are highly superimposable, with
minor deviations confined to the termini and loop L4, which lacks
electron density for three residues (Figure S6). ConSurf (Ashke-
nazy et al., 2010; Glaser et al., 2003) analysis across the entire–1393, August 4, 2015 ª2015 Elsevier Ltd All rights reserved 1383
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Figure 1. Structure of BRAF RBD
(A) Sequence alignment of the RAS-binding do-
mains from the three human RAF kinase isoforms.
Sequences, obtained from the RAF-like RBD pro-
tein domain family PF02196 (Finn et al., 2014), were
aligned using Clustal Omega (Sievers et al., 2011)
and the sequence alignment was rendered using
ESPript 3.0 (Robert and Gouet, 2014). Boxed resi-
dues represent identical (white font, highlighted in
red) and similar (red font) amino acid conservation.
Residue numbering for BRAF RBD and secondary
structural elements from its solution NMR structure
(PDB: 2L05) are drawn above the alignment.
(B) Final ensemble of 20 conformers comprising the
solution NMR structure of BRAF RBD (PDB: 2L05).
Residues 149–232 are shown.
(C) X-Ray crystal structure of BRAF RBD (PDB:
3NY5). Residues 151–233 are shown; dotted lines
represent missing electron density in the loop (L4)
between strands b3 and b4.
(D) ConSurf conserved residue analysis for the
entire PF02196 protein domain family (Pfam 27.0;
710 sequences) rendered on the solution NMR
structure of BRAF RBD (residues 155–227).
Residue coloring, reflecting the degree of residue
conservation across the family, ranges from
magenta (highly conserved) to cyan (variable).
(E) Superposition of BRAF RBD crystal structure
(blue; residues 153–228) and the crystal structure
of CRAF RBD (residues 54–131) in complex with
HRAS (orange; PDB: 4G0N) (Fetics et al., 2015).
The structure of HRAS has been omitted. All
structures were rendered using PyMOL (PyMOL
Molecular Graphics System, Version 1.4; Schro¨-
dinger LLC).Pfam RAF-like RAS-binding protein domain family, PF02196
(Finn et al., 2014), reveals that amino acid conservation is primar-
ily clustered on the region of the domain encompassing b1 and
b2 strands and the C terminus of a1 helix (Figure 1D).
A Dali search (Holm and Rosenstro¨m, 2010) for structurally
similar proteins showed significant (high Z score) hits with the
RBD of CRAF in complex with HRAS (Dali Z score 13.9; PDB:
4G0N-B, Ca RMSD 0.8 A˚) (Figure 1E) and ubiquitin (Dali Z score
9.6, PDB: 3HM3-D, Ca RMSD 2.1 A˚). X-Ray crystal structures of
CRAF RBD bound to the RAS homolog Rap1A (Nassar et al.,
1995) and, very recently, HRAS itself (Fetics et al., 2015) reveal
that complex formation is mediated by an intermolecular interac-
tion between two antiparallel b strands: the b2 strand of the RBD
and b2 of HRAS or Rap1A. Interestingly, the RBDs from BRAF
and CRAF share 100% sequence identity in the functionally
important b1 and b2 strands (157RVFLPNKQRTVV169). Such1384 Structure 23, 1382–1393, August 4, 2015 ª2015 Elsevier Ltd All rights reservedsequence conservation suggests a highly
similar HRAS binding mode for the BRAF
and CRAF RBDs, which we have verified
(see below).
BRAF RBD Forms a Ternary
Complex with HRAS and GppNHp
To facilitate tight and persistent complex
formation with BRAF RBD, bacterially ex-
pressed HRAS GTPase isolated in theGDP form must be bound to a non-hydrolyzable GTP analog,
such as GppNHp. Using 31P NMR, we confirmed the complete
enzymatic conversion of HRAS-GDP to HRAS-GppNHp and
subsequent complex formation with BRAF RBD, which results
in a small upfield shift of the g-phosphate 31P resonance typically
observed upon effector binding (Spoerner et al., 2004) (Fig-
ure 2A). Both analytical gel filtration with static light-scattering
detection (Figure 2B) and rotational correlation times determined
from 15N relaxation data (Figure 2C) reveal that the BRAF RBD
and HRAS domains are monomers in solution, and that the re-
sulting complex, RBD-HRAS-GppNHp, exhibits the molecular
weight and tc changes expected for this ternary complex. As a
consequence, the 15N T1 and T2 values for BRAF RBD, HRAS,
and the complex follow the expected trend of increasing T1
and decreasing T2 with increasing macromolecular weight, in
the slow motion limit (u0tc >> 1) (Figure 2D).
AC
D
B Figure 2. Assessment of Phosphorylation
and Oligomerization States of Free and
Complexed BRAF RBD and HRAS
(A) 1D 31P NMR spectra at 298 K of 0.6 mMHRAS-
GDP (prior to alkaline phosphatase treatment),
0.6 mM HRAS-GppNHp after alkaline phospha-
tase treatment and reconstitution with GTP
analog, and 0.3 mM [13C,15N]-BRAF RBD-HRAS-
GppNHp. The 31P resonances for HRAS-bound
GppNHp are labeled following the latest literature
assignments (Spoerner et al., 2005).
(B) Analytical gel filtration/static light-scattering
data for 0.6 mM [13C,15N]-BRAF RBD-HRAS-
GppNHp at pH 7.5. Plots of relative differential
refractive index (dn/dc) and experimental molec-
ular weight (34.9 kDa) are shown in blue and red,
respectively. The expected molecular weight of
the complex, including isotope enrichment, non-
native residues, and the nucleotide, is 31.8 kDa.
(C) Plots of rotational correlation time (tc) deter-
mined from 15N T1 and T2 relaxation data as
a function of protein molecular weight for
0.3–0.4 mM [U-13C,15N]-BRAF RBD (blue), [15N]-
HRAS-GDP (magenta), and [13C,15N]-BRAF
RBD-HRAS-GppNHp (green) at 298 K and pH 7.5;
knownmonomeric proteins solved in theNortheast
Structural Genomics project are shown in red.
(D) Plots of 60.82 MHz 15N T1 (left) and T2 (right)
relaxation data for [U-13C,15N]-BRAF RBD (blue),
[U-15N]-HRAS-GDP (magenta), and [U-13C,15N]-
BRAF RBD-HRAS-GppNHp (green) at pH 7.5 and
298 K.RAS Binding to BRAF RBD Results in Local and
Long-Range CSPs
The effects of HRAS binding on BRAF RBD can be elucidated at
an atomic level by comparing NMR spectral changes between
apo and bound forms resulting from HRAS-GppNHp binding
to [13C,15N]-BRAF RBD. Plots of HRAS-induced backbone
amide, DdNH, and carbonyl, DdCO, CSPs along the sequence
of BRAF RBD are shown in Figures 3A and 3B. The most dra-
matic amide and carbonyl CSPs correspond to key residuesStructure 23, 1382–1393, August 4, 2015 ªlocated in b2 strand (R166 and V168)
and the end of a1 helix (M187). These
trends correlate well with the HRAS-
binding epitope of CRAF RBD, charac-
terized by both X-ray crystallography
(Fetics et al., 2015) and NMR CSPs
(Emerson et al., 1995; Terada et al.,
1999), in which the b2 strand of the
RBD forms a network of intermolecular
hydrogen bonds and the C-terminal end
of a1 helix also mediates complex forma-
tion. For example, in the crystal structure
of CRAF RBD-HRAS-GppNHp (PDB:
4G0N) (Fetics et al., 2015), the backbone
NH of R67, CO of R67, and NH of V69
(corresponding to R166 and V168,
respectively, in BRAF) interact with com-
plementary moieties on b2 strand of
HRAS, before this strand veers awayfrom the RBD (Figure 4A). This pattern is recapitulated exactly
in our backbone CSPs for HRAS binding to BRAF RBD; namely,
very large DdNH values for R166 and V168, but only a large DdCO
for R166 but not V168. The residue at the C-terminal end of a1
helix in CRAF RBD, V88, is completely buried in the protein-
protein interface, including its backbone carbonyl oxygen (Fig-
ure 4B). The corresponding residue in BRAF RBD, M187, also
exhibits sizable DdCO and DdNH CSPs consistent with a similar
mode of binding for BRAF RBD. We observe no significant2015 Elsevier Ltd All rights reserved 1385
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Figure 3. NMR Chemical Shift Perturbations in BRAF RBD Resulting
from HRAS Binding
Plots of (A) backbone amide (DdNH) and (B) carbonyl (DdCO) CSPs versus
residue number for BRAF RBD. Mean CSP values are indicated by blue lines,
and residues exhibiting the largest CSPs are labeled. Secondary structural
elements in BRAF RBD (PDB: 2L05) are shown above the plots.backbone amide CSPs for BRAF RBD in the presence of the
GDP form of HRAS (data not shown).
Mapping CSPs due to HRAS binding onto the structure of
BRAF RBD yields further insights into the structural effects of
complex formation. As expected, the largest backbone amide
(Figure 5A) and side chain (Figure 5B) CSPs (in red) are generally
clustered at the HRAS-binding interface. Even more significant
are the numerous CSPs observed throughout the RBD structure,
extending far beyond the RAS-binding epitope. Interestingly,
these perturbations are propagated through much of the core
of the domain, reflected by several backbone amide (including
b1: R158, V159; b5: L222, H223), buried methyl (including b1:
V157g1, V159g1/g2; b2: T167g2, V169g2; a1: L181d1, A184b,
L185d1/d2; b3: V197g1/g2; b4: I208d1; a2: I214d1; b5: L222d2,
V224g2), and indole NH (W210ε1) CSPs (Figures 5A and 5B).
These results indicate allosteric conformational changes in
BRAF RBD due to HRAS binding.
19F NMR to Probe for RAS Binding
To further probe the allosteric changes induced by HRAS bind-
ing, we incorporated 5-fluorotryptophan (5-F-Trp) into BRAF
RBD and monitored complex formation using 19F NMR. BRAF1386 Structure 23, 1382–1393, August 4, 2015 ª2015 Elsevier Ltd AlRBD features a conserved tryptophan, W210, whose side chain
is buried in the core of the a/b structure, and a second solvent-
exposed tryptophan, W216, jutting out from helix a2 (Figure 6A).
The z3 position in the analogous conserved buried tryptophan
(W114) in CRAF RBD is more than 15 A˚ from the nearest HRAS
backbone atom at the intermolecular strand-strand interface of
the complex. Due to the numerous highly favorable properties
of the 19F nucleus, including its high resonance frequency and
the extraordinary sensitivity of its chemical shift to its local envi-
ronment (Kitevski-LeBlanc and Prosser, 2012; Yu et al., 2013),
we reasoned that 19F NMR combined with 5-F-Trp incorporation
could serve as a sensitive monitor of HRAS conformational
changes upon binding to BRAF RBD. The 19F NMR spectrum
of 5-F-Trp-labeled BRAF RBD exhibits two 19F resonances in
the expected chemical shift window (Figure 6B), which can be
assigned on the basis of the solvent-induced isotope shift effect
(Kitevski-LeBlanc and Prosser, 2012). Specifically, fully exposed
fluorinated residues exhibit a Dd z 0.2 ppm upfield shift in
2H2O. In the case of 5-F-Trp-labeled BRAF RBD, the upfield
19F signal experiences a marked 0.16 ppm shift when the sol-
vent is changed from 10% to 90% 2H2O, and is thus assigned to
the exposed W216, whereas the downfield 19F resonance corre-
sponding to the buried W210 experiences little dependence on
solvent deuteration (Figure 6B). The titration of 5-F-Trp-labeled
BRAFRBDwith unlabeledHRAS-GppNHp is shown in Figure 6C.
We observe classic slow exchange binding behavior, in which
separate 19F signals for W210 in the apo (a) and bound (b) states
decrease and increase, respectively, during the course of the
titration. Such slow exchange behavior is expected for the re-
ported high-affinity, low-nanomolar binding of HRAS-GTP to
BRAF RBD (KD = 11.2 nM) (Fischer et al., 2007), and is also
observed in the backbone 1H-15N chemical shift timescale (Ter-
ada et al., 1999). Moreover, the 19F signal due toW210 exhibits a
significant CSP (Dd = 0.16 ppm) induced by RAS binding,
which is approximately twice as large as the side chain NH
CSP observed for this residue (Figure 5B). The 19F signal due
to W216 in helix a2 also exhibits a very small CSP (Dd = 0.04
ppm). These results confirm that HRAS binding induces confor-
mational changes that are sensed in the core of the RBD struc-
ture, distant from the HRAS-binding interface, by 19F NMR.
RAS Binding Changes the Free-Energy Landscape of
BRAF RBD
To further characterize the conformational changes resulting
from the binding of HRAS-GppNHp to BRAF RBD, wemeasured
backbone amide hydrogen/deuterium exchange rates on both
unbound and complexed RBD by NMR. In the limit of EX2 amide
exchange conditions (Krishna et al., 2004), the experimentally
determined residue-specific amide exchange rates, kex, for
the protected amides can be converted to stabilization free en-
ergies, DGHX. When plotted across the RBD sequence, we
observe a marked increase in DGHX (decrease in kex) across the
sequence for the complex (in blue) comparedwith the apoprotein
(in red) (Figure 7A). These include several additionally protected
backbone amides in the complexed RBD, which are not pro-
tected in the free RBD. When mapped onto the 3D structure of
BRAF RBD, we observe that these increases in the free energy
of local and/or global conformational unfolding are transmitted
throughout several secondary structure elements, includingl rights reserved
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B Figure 4. Key Interfacial Residues in CRAF
RBD-HRAS Structure
(A) Conserved residues involved in intermolecular
strand-strand hydrogen bonding in the crystal
structure of CRAF RBD-HRAS (PDB: 4G0N) (Fet-
ics et al., 2015). Residues R67 and V69 in CRAF
correspond to R166 and V168 in BRAF.
(B) View from the same structure showing the
environment around the C terminus of helix a1
from CRAF RBD and the buried carbonyl of V88
(corresponding to M187 in BRAF). Hydrogen
atoms were added onto the structure using Mol-
Probity 4.1 (Davis et al., 2007). Structures were
rendered using PyMOL.much of the b sheet and helices a1 and a2 (Figure 7B). A similar
picture is obtained when the changes in amide exchange rates
uponHRASbinding, expressed as ln(kex
apo/kex
complex), are repre-
sented on the structure of BRAF RBD (Figure 7C). Here, positive
values reflect a decrease in kex, increased protection from
exchange with solvent deuterons, and reduced protein flexibility
upon complex formation, whereas negative values indicate
increased kex and enhanced backbone motion induced by
HRAS. The slowed amide exchange is not simply due to stabiliz-
ing a single conformation of RBDupon complex formation, as not
all buried amide protons exhibit the same degree of reduced ex-
change rates in the complex. In fact, residue K206 in b4 strand,
which exhibits a fast but measurable kex in the apoprotein, ex-
changes more rapidly in the complex. Taken together, these re-
sults demonstrate that RASbinding significantly alters the energy
landscape of BRAF RBD, suggesting a shift from a structured yet
somewhat dynamic, ‘‘breathing’’ apoprotein to a less conforma-
tionally dynamic bound domain structure.
DISCUSSION
In this study we present the solution and crystal structures of the
RBD from BRAF kinase and characterize its complex with HRAS
bound to a non-hydrolyzable analog of GTP, GppNHp, in solu-
tion. The solution and crystal structures of BRAF RBD confirm
the classic ubiquitin a/b roll expected for RAS-binding domains.
NMR CSPs for BRAF RBD resulting from HRAS-GppNHp bind-
ing corroborate the conserved RAS-binding epitope, but also
demonstrate unexpected allosteric conformational changes
that propagate from the binding epitope through the core of
the RBD to distal elements in the domain. Moreover, backbone
amide hydrogen/deuterium exchange NMR results reveal a gen-
eral yet varied decrease in amide exchange rates across the
structure of the domain upon HRAS binding. These changes inStructure 23, 1382–1393, August 4, 2015 ªamide exchange rates distant from the
RAS-binding epitope reveal a distribution
of conformations in apo-RBD that are
altered in the complex. This shift in
conformational distribution is also indi-
cated by CSPs in sites distant from the
RAS-binding site upon complex forma-
tion. These data support an allosteric
model for the RAS/RAF interaction, and
suggest a mechanism by which RASbinding can signal the drastic domain rearrangements required
for activation of BRAF kinase.
Two main conclusions can be drawn from our NMR studies of
the BRAF RBD-HRAS-GppNHp complex. First, our CSP results
on BRAF RBD demonstrate that the mode of RAS binding previ-
ously established for the CRAF isoform (Emerson et al., 1995;
Fetics et al., 2015; Terada et al., 1999) is preserved in BRAF.
Namely, specific determinants at the binding interface comprise
conserved residues in the C-terminal region of helix a1 and inter-
molecular strand-strand hydrogen bonding mediated by the b2
strand of the RBD. Moreover, the expected interfacial methyl
and amide side chains in BRAF RBD exhibit the largest CSPs
upon HRAS binding, namely the methyls of T167, V169, and
M187, and the NH2 of Q165 (Figure 5A). Taken together, these
results indicate that the isoforms of RAF interact with RAS in a
highly analogous fashion.
Second, the backbone amide and side-chain 1H, 13C, and
15N CSPs, and buried Trp 19F CSPs reported here clearly
demonstrate that RAS binding to BRAF RBD results in a network
of perturbations that extend into the RBD far beyond the imme-
diate protein-protein interface. In addition, backbone amide
hydrogen/deuterium exchange studies reveal that RAS binding
results in dramatic changes in amide proton exchange rates
permeating much of the secondary structure elements in the
domain. The observation of both (predominantly) slower and
(infrequent) faster backbone amide exchange rates in BRAF
RBD induced by HRAS binding is consistent with a shift in the
conformational distributions of the BRAF RBD structure upon
complex formation. Taken together, these data demonstrate
an allosteric change in the RBD structure due to RAS binding,
which could provide the basis for its interactions with other do-
mains in BRAF and/or other proteins.
The concept of allostery in this system was previously pro-
posed on the basis of molecular dynamics (MD) simulations on2015 Elsevier Ltd All rights reserved 1387
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Figure 5. HRAS-Induced CSPs Mapped onto the Structure of BRAF
RBD
(A) Backbone amide CSPs (DdNH) mapped onto the solution NMR structure of
BRAF RBD. Residues in the structure are colored according to the magnitude
of their CSP compared with the mean, as follows: blue, CSP < mean; green,
mean < CSP < mean + 1s; yellow, mean + 1s < CSP < mean + 2s; red, CSP >
mean + 2s (mean CSP = 0.1 ppm; s = 0.1 ppm, excluding major outliers).
(B) Methyl (DdMe) and side-chain NH (DdNH) CSPs mapped onto the solution
NMR structure of BRAF RBD. Methyl carbon and side-chain nitrogen atoms
are represented as spheres, and colored using the same scheme as in (A)
(mean CSP = 0.06 ppm; s = 0.07 ppm, excluding M187). Side-chain reso-
nances present in the apoprotein spectra but not assigned in the complex are
shown in orange. Structures were rendered using PyMOL.theCRAFRBD-HRAScomplex,where complex formation results
in dynamic changes in the RBDemanating from the binding inter-
face and ‘‘percolating’’ through the core of the structure via a
network of interacting residues (Gohlke et al., 2003, 2004). Spe-
cifically, the MD calculations on apo and bound CRAF RBD pre-
dicted an increase in the rigidity of the b sheet of the RBD and
increased flexibility of loop L4 in CRAF RBD upon complex for-
mation. More recent MD studies confirmed the same principal
network of coupled interactions in which the cluster R67, F61,
andQ127 (R166, F160, andH223 inBRAF) plays a key role (Fetics
et al., 2015). Moreover, both structural and MD results for the
oncogenicQ61Lmutant of HRAS indicate an altered allosteric ef-
fect on CRAF RBD, resulting in greatly reduced flexibility of loop
L4 upon complex formation (Fetics et al., 2015). The results pre-
sented here on BRAF, which like ARAF features a much shorter
loop L4 (Figure 1A), extend this idea of dynamic allostery to1388 Structure 23, 1382–1393, August 4, 2015 ª2015 Elsevier Ltd AlBRAF RBD and provide direct spectroscopic evidence that
the RAS-binding signal is transmitted via both backbone and
side-chain conformational changes in BRAF RBD. Specifically,
our solution NMR data reveal that the RAS-binding signal is
also transmitted through several buried side chains in the core
of the RBD, in addition to the in silico predicted network of resi-
dues on the surface of the aforementioned b sheet.
In recent years numerous structural, spectroscopic, and MD
studies have established that the structure of the RAS protein
is also highly dynamic, featuring several conformational sub-
states whose populations can be modulated by the phosphor-
ylation state and nature of the bound guanosine nucleotide,
interactions with effector proteins, and mutations in RAS itself
(Fetics et al., 2015; Rosnizeck et al., 2014; Smith and Ikura,
2014; Spoerner et al., 2010). In the GTP-bound state, for
example, RAS adopts two major conformational states, termed
state 1(T) and state 2(T), which have disparate functions; state
1(T) exhibits a lower affinity for effector proteins and is recog-
nized by GEFs, whereas binding of effector proteins strongly
shifts the equilibrium toward state 2(T) (Spoerner et al., 2010).
Manipulation of the conformational equilibrium between states
1(T) and 2(T) by RASmutations, particularly in switch I, and inhib-
itor binding can abrogate or alter binding to effector proteins
(Rosnizeck et al., 2014; Smith and Ikura, 2014; Spoerner et al.,
2004). In light of the results presented here on BRAF RBD and
recent studies on CRAF RBD (Fetics et al., 2015), it is interesting
to note that the allosteric changes that originate from the binding
interface observed in RAF-RAS complexes result from a high-
affinity interaction between two proteins which each have their
own conformational plasticity.
Finally, the interplay between conformational dynamics, mo-
lecular plasticity, and allostery is emerging as a central paradigm
for understanding the basis of molecular recognition, regulation,
and signaling in nature (Motlagh et al., 2014). The historic percep-
tion of protein structure as being static has been supplanted in
recent years by a more dynamic view centered on the concept
of conformational selection (Boehr et al., 2009), whereby proteins
fluctuate between a range of structures and are thereby predis-
posed for interaction with binding partners (Huang and Monte-
lione, 2005). To this end, NMR relaxation techniques have taken
center stage in establishing the link between the intrinsic internal
conformational dynamics of proteins, even for buried methyl-
bearing residues, andmacromolecular recognition and allosteric
regulation (Aramini et al., 2014; Sekhar and Kay, 2013; Tzeng and
Kalodimos, 2011, 2012; Wand, 2013). Moreover, b-sheet struc-
tures are particularly well suited formediating allostery and signal
transduction via correlated backbone motions causing global
sheet bending and twisting, resulting in ‘‘channels of communi-
cation’’ running perpendicular to the strands (Fenwick et al.,
2014). In accordance with these views, the results presented
here provide empirical evidence that RAS binding is translated
through the RBD structure via conformational perturbations.
Since the exact structural basis for how RAS binding to RAF
kinases unlocks the inactive multi-domain structure of RAF and
how this event ultimately leads to a catalytically active kinase
remains an open question, this work provides a starting point
for further investigations into how the binding of RAS, as well as
oncogenic RAS mutants, alters allosterically regulated domain-
domain interactions in the full-length BRAF kinase.l rights reserved
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Figure 6. 19F NMR as a Probe for HRAS
Binding to BRAF RBD
(A) Locations of the two 5-F-Trp residues in the
NMR structure of BRAF RBD. The fluorine atoms
are shown as magenta spheres. The secondary
structure elements were rendered (PyMOL) with
some transparency to completely show the buried
W210 side chain.
(B) Assignment of the 19F signals from 0.45 mM
5-F-Trp-labeled BRAF RBD using the solvent-
induced isotope shift effect. Dotted lines indicate
the shift of the 19F signal for W216 with increasing
percentage of 2H2O in the buffer.
(C) Titration of 0.2 mM 5-F-Trp-labeled BRAF RBD
with HRAS-GppNHp monitored by 19F NMR at
293 K. Resonances for W210 in the apo and bound
states are labeled with a and b, respectively.EXPERIMENTAL PROCEDURES
Cloning, Expression, Purification, and Sample Preparation
RBD from human serine/threonine-protein kinase BRAF (UniProtKB/Swiss-
Prot: P15056, BRAF_HUMAN; NESG: HR4694F) and the first 171 residues
(out of 189 in the mature protein) of human HRAS (UniProtKB/Swiss-Prot:
P01112, RASH_HUMAN; NESG: HR9664), referred to here as BRAF RBD
and HRAS, respectively, were cloned, expressed, and purified based on
the standard procedures of the NESG (Acton et al., 2011). Complete clon-
ing, protein expression, purification, and sample preparation protocols are
provided in Supplemental Experimental Procedures. In brief, isotopically
enriched BRAF RBD for NMR spectroscopy and X-ray crystallography
(BRAF[149–232] and BRAF[153–237], respectively), each containing an
11-residue N-terminal affinity tag (MGHHHHHHSHM), were expressed in
Escherichia coli BL21(DE3)-Gold cells (Agilent) grown in MJ9 minimal me-
dium (Jansson et al., 1996) containing U-(15NH4)2SO4 and [U-
13C]-glucose
as the sole nitrogen and carbon sources for NMR, or supplemented with
selenomethionine for crystallography (Doublie et al., 1996). Incorporation
of 5-F-Trp into BRAF RBD was performed as previously described (Aramini
et al., 2014). Tagless and unlabeled HRAS used for binding studies with
BRAF RBD was expressed in E. coli Tuner(DE3) cells (EMD Millipore) grown
in LB medium and cleaved using N-terminal hexaHis-tagged TEV protease
(Kapust et al., 2001). To activate HRAS for binding to BRAF RBD, the
purified bacterially expressed GDP form of HRAS was treated with calf in-
testinal alkaline phosphatase (New England BioLabs) in the presence of a
non-hydrolyzable analog of GTP, GppNHp (Sigma) (Smith and Rittinger,
2002). Samples of [U-13C,15N]- and [U-5%-13C,100%-15N]-BRAF RBD for
NMR structure determination were concentrated by centrifugation to 0.7–
0.9 mM in 20 mM ammonium acetate, 100 mM NaCl, 10 mM DTT, 5 mM
CaCl2, 50 mM 2,2-dimethyl-2-silapentane-5-sulfonic acid (DSS), and 10%
2H2O (v/v) at pH 4.5. Samples of 0.3–0.6 mM [U-
13C,15N]-BRAF RBD-
HRAS-GppNHp complex for NMR spectroscopy were prepared in 20 mM
Tris-HCl, 100 mM NaCl, 1 mM tris(2-carboxyethyl)phosphine (TCEP),
5 mM MgCl2, 50 mM DSS, 10% (v/v)
2H2O at pH 7.5 by combining equi-
molar amounts of apo-[U-13C,15N]-BRAF RBD and unlabeled HRAS-
GppNHp in the same buffer followed by concentration by centrifugation.
Samples of 5-F-Trp BRAF RBD for 19F NMR spectroscopy were concen-
trated to 0.2–0.5 mM in pH 7.5 buffer (see above). All pET expression vec-
tors used in this work have been deposited in the PSI Materials Repository
(http://psimr.asu.edu/).Structure 23, 1382–1393, August 4, 2015Static Light-Scattering Measurements
The oligomerization states of free BRAF RBD and
HRAS, and the stoichiometry of their complex,
were assessed by analytical gel filtration coupled
with static light scattering and molecular rotational
correlation times determined from 15N T1 and T2
relaxation measurements (see below). Analytical
gel filtration with multi-angle static light-scatteringdetection data were collected at l = 690 nm on a miniDAWN (TREOS) Light
Scattering instrument (Wyatt Technology) coupled with an analytical gel filtra-
tion column. All measurements were performed at room temperature and
with a flow rate of 0.5 ml/min. Data were analyzed using the ASTRA software
package (Wyatt Technology).
NMR Spectroscopy
All 1H, 13C, and 15N NMR data were collected at 298 K on Bruker AVANCE
600- and 800-MHz spectrometers equipped with 1.7-mm TCI and 5-mm
TXI cryoprobes, respectively, processed with NMRPipe (Delaglio et al.,
1995), and visualized using SPARKY 3 (T.D. Goddard and D.G. Kneller, Uni-
versity of California San Francisco). All spectra were referenced to internal
DSS. 1D 31P NMR spectra were acquired at 298 K on a Bruker AVANCE III
500-MHz spectrometer equipped with a 5-mm QCI-P cryoprobe at a reso-
nance frequency of 202.65 MHz, using a 3.0-s repetition time, 20,000-Hz
sweep width, and 1,000–1,600 scans. 1D 19F NMR spectra were acquired
locked and at 20C on a Varian INOVA 500-MHz spectrometer equipped
with a room-temperature 5-mm 1H/19F switchable probe at a frequency of
470.18 MHz, using a 5.35-s repetition time, 20,000-Hz sweep width, and
1,000–4,000 scans, and referenced to external neat CFCl3 (Aramini et al.,
2014). 31P and 19F spectra were processed with 5- and 10-Hz exponential
multiplication, respectively, and analyzed using Mnova 9.0 (Mestrelab
Research). Near complete 1H, 13C, and 15N resonance assignments for
BRAF RBD at pH 4.5 were determined using conventional triple-resonance
NMR methods (see Supplemental Experimental Procedures). In brief, auto-
mated backbone resonance assignments were made using PINE 1.0 (Bah-
rami et al., 2009), and the final connectivity information was visualized
and confirmed using AutoAssign 2.4.0 (Moseley et al., 2001). Side-chain
assignments were completed manually using 3D HBHA(CO)NH, HBHANH,
HCCH-COSY, HCCH-TOCSY, and (H)CCH-TOCSY experiments. The final
resonance assignments, NOESY spectral peak lists, and time domain data
for BRAF RBD were deposited in the BioMagResDB (BMRB: 17030). Back-
bone resonance assignments of apo-[13C,15N]-BRAF RBD at pH 7.5 were
confirmed using standard 3D triple-resonance NMR experiments. Backbone
and side-chain methyl resonance assignments of [13C,15N]-BRAF RBD in
complex with HRAS-GppNHp at pH 7.5 were deduced on the basis of
TROSY-based 3D triple-resonance backbone experiments, and 3D (H)
CCH-TOCSY and 13C- and 15N-edited NOESY spectra, respectively. Global
protein rotational correlation times (tc) were computed from the ratio of
15N
T1 and T2 relaxation times, derived from pseudo-2D
15N-edited T1 and T2ª2015 Elsevier Ltd All rights reserved 1389
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Figure 7. Backbone Amide Hydrogen/Deuterium Exchange NMR
Reveals Changes in the Free Energy Landscape of BRAF RBD
upon HRAS Binding
(A) Stacked bar graphs of stabilization free energies (DGHX) computed from
backbone amide exchange rates (kex) versus sequence for apo (red, top) and
complexed (blue, bottom) BRAF RBD. Secondary structural elements in BRAF
RBD are shown above the plots.
(B) Free energies of amide exchange (DGHX) mapped onto the solution
NMR structure of apo (left) and complexed (right) BRAF RBD. Residues in
each structure are colored as a function of DGHX (kcal/mol) as follows: red, <5;
yellow, 5 < DGHX < 6; green, 6 < DGHX < 7; cyan, 7 < DGHX < 8; blue, >8.
Increasing DGHX correlates with increasing amide protection from exchange.
(C) Ratios of backbone amide exchange rates for apo (kex
apo) andHRAS-bound
(kex
complex) BRAF RBDmapped onto its solution NMR structure (residues 154–
228 shown). In cases where the exchange rate was too fast to be accurately
measured, an upper limit of kex = 0.001 s
1was assumed.Residues are colored
as a function of ln(kex
apo/kex
complex) as follows: red, <0; yellow, 0–1; green, 1–2;
cyan, 2–3; blue, 3–4; purple, >4; white, not measureable in both states. The
approximate position of HRAS encompassing the binding interface, based on
the crystal structure of its complex to CRAF RBD (PDB: 4G0N) (Fetics et al.,
2015), is shown in orange. Structures were rendered using PyMOL.
1390 Structure 23, 1382–1393, August 4, 2015 ª2015 Elsevier Ltd Al(CPMG) relaxation experiments (Farrow et al., 1994), and the nuclear fre-
quency (nN) according to Equation 1 (Fushman et al., 1994; Kay et al., 1989).
tcz
 ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
6T1
T2
 7
s !,
4pnN: (Equation 1)
Solution NMR Structure Refinement
The solution NMR structure of BRAF RBD was calculated using CYANA 3.0
(Gu¨ntert et al., 1997; Herrmann et al., 2002) supplied with peak intensities
from 3D 15N-edited NOESY (tm = 100 ms), 3D
13C-edited aliphatic NOESY
(tm = 100 ms), and 3D
13C-edited aromatic NOESY (tm = 120 ms) spectra,
together with broad dihedral angle constraints derived by TALOS+ (Shen
et al., 2009) (f, c ± 30) for ordered residues with confidence scores of 10.
The 20 structures with lowest target function out of 100 calculated in the final
cycle were further refined by restrained MD in explicit water using CNS 1.2
(Bru¨nger et al., 1998; Linge et al., 2003) and the PARAM19 force field, supplied
with the final NOE-derived distance and TALOS+ dihedral angle constraints.
The final refined ensemble of 20 structures for BRAF RBD (excluding the first
nine residues of the N-terminal 6xHis purification tag) was deposited in the
PDB (PDB: 2L05). Structural statistics and global structure quality factors
(Table S1) were computed using the PSVS 1.5 (Bhattacharya et al., 2007)
and MolProbity (Davis et al., 2007) servers. The global goodness-of-fit of the
final structure ensemble with the NOESY peak list data and resonance assign-
ments was determined using the RPF server (Huang et al., 2005, 2012).
Crystallization, Data Collection, and Structure Refinement
Crystallization screening was performed using a microbatch-under-oil crystal-
lization method at 18C (Chayen et al., 1990). After optimization, BRAF RBD
crystals useful for structure determination were grown in drops composed of
1.0 ml of protein and 1.0 ml of precipitant solution (100 mM Bis-Tris [pH 6.5],
28% [w/v] PEG 2000) under paraffin oil (Hampton Research). The crystals
were cryoprotected with 15% ethylene glycol prior to flash-freezing in liquid
nitrogen for data collection. A selenomethionyl single-wavelength anomalous
diffraction (SAD) data set (Hendrickson, 1991) was collected at the peak wave-
length of the selenium K edge using beamline X4A at the National Synchrotron
Light Source (l = 0.97903 A˚). The diffraction data from a single crystal was pro-
cessed with the HKL2000 package (Otwinowski and Minor, 1997).
The program SHELXE/D (Schneider and Sheldrick, 2002) was used to locate
a selenium site and to calculate phases to 2.6 A˚ resolution. The model was
completed using iterative cycles of manual rebuilding in Coot (Emsley and
Cowtan, 2004), and was refined against 1.99 A˚ data with the program PHENIX
(Adams et al., 2002). The data processing and refinement statistics for the
crystal structure determination are summarized in Table S2. The quality of
the final structure was assessed using PSVS (Bhattacharya et al., 2007) and
PROCHECK (Laskowski et al., 1993). The atomic coordinates and structure
factors are available in the PDB under accession code PDB: 3NY5.
NMR CSP Measurements
CSPs on BRAF RBD resulting from complex formation with HRAS were
computed from 2D 1H-15N TROSY-HSQC, TROSY- and standard 3D HNCO,
and 2D 1H-13C HSQC spectra of [13C,15N]-BRAF RBD, free and in complex
with HRAS-GppNHp acquired at identical field strength, temperature, and
buffer conditions (800 MHz, 298 K, pH 7.5). Composite 1H and 15N backbone
amide chemical shift perturbations, DdNH, were calculated using Equation 2
with weighting factors, uH and uN, of 1.0 and 0.154, respectively; carbonyl
CSPs weremultiplied by aweighting factor,uCO, of 0.341 (Evena¨s et al., 2001).
DdNH =
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðuHDdHÞ2 + ðuNDdNÞ2
q
: (Equation 2)
Composite side-chain methyl CSPs were computed using Equation 3.
DdMe =
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðDdHÞ2 + ðDdC=4Þ2
q
: (Equation 3)
Hydrogen/Deuterium Exchange NMR Experiments
Exchange rates for slowly exchanging backbone amides were measured by
NMR using the following procedure. Samples of 0.5–0.6 mM [13C,15N]-BRAFl rights reserved
RBD free or in complex with HRAS-GppNHp in pH 7.5 buffer were lyophilized
and redissolved in the same volume (50 ml) of 2H2O and immediately placed
into a 1.7-mm microtube for NMR. The NH signal intensities for slowly
exchanging backbone amides were then measured over time in a series of
600-MHz 2D 1H-15N SOFAST HMQC spectra (Schanda and Brutscher,
2005) at 298 K. Amide exchange rates, kex, were obtained by exponential fitting
of the signal intensity decays using KaleidaGraph 4.0 (Synergy Software).
According to the classic Linderstrøm-Lang model, the exchange of structur-
ally protected amide hydrogen atoms with solvent proceeds through a tran-
siently exposed state according to Equation 4 (Krishna et al., 2004):
N Hclosed %
kop
kcl
N Hopen/kint N2H; (Equation 4)
where kop and kcl are the rate constants of opening and closing, and kint is
the intrinsic amide exchange rate, which depends on residue type, neigh-
boring sequence, pH, and temperature. Under conditions of EX2 exchange
(kcl[ kint), the free energy of amide exchange per residue can be computed
using Equation 5 (Krishna et al., 2004).
DGHX =  RT lnðkex=kintÞ: (Equation 5)
Hence, knowledge of the empirical amide exchange rates, kex, and intrinsic
exchange rates, kint, obtained for the BRAF RBD protein sequence using the
Sphere server (www.fccc.edu/research/labs/roder/sphere/) (Bai et al., 1993),
yields DGHX for slowly exchanging amides.
ACCESSION NUMBERS
The PDB and BioMagRes DataBank accession numbers for the structures
presented in this paper are PDB: 2L05 and BMRB: 17030 (NMR) and PDB:
3NY5 (X-ray).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and two tables and can be found with this article online at http://
dx.doi.org/10.1016/j.str.2015.06.003.
AUTHOR CONTRIBUTIONS
Conceptualization: J.M.A., S.M.V., Y.J.H., L.T., G.T.M. Investigation: J.M.A.,
S.M.V., L.M.T., H.J., E.T.C., J.S., M.S., T.B.A., R.X. Writing—original draft:
J.M.A., S.M.V., L.T., G.T.M. Writing—review and editing: J.M.A., S.M.V.,
L.T., G.T.M.
ACKNOWLEDGMENTS
We thank I. Pelczer and K. Conover for assistancewith acquiring 31PNMRdata
at Princeton University, and S. Anderson, S. Arunkumar, D. Case, C. Cicco-
santi, J. Everett, S. Krishna Murthy, D. Patel, R. Shastry, and R. Tejero for
valuable discussions and technical support. This work was supported by a
grant from the National Institute of General Medical Sciences Protein Structure
Initiative U54-GM094597 (to G.T.M.).
Received: April 8, 2015
Revised: May 27, 2015
Accepted: June 4, 2015
Published: July 9, 2015
REFERENCES
Acton, T.B., Xiao, R., Anderson, S., Aramini, J., Buchwald, W.A., Ciccosanti,
C., Conover, K., Everett, J., Hamilton, K., Huang, Y.J., et al. (2011).
Preparation of protein samples for NMR structure, function, and small-mole-
cule screening studies. Methods Enzymol. 493, 21–60.
Adams, P.D., Grosse-Kunstleve, R.W., Hung, L.W., Ioerger, T.R., McCoy,
A.J., Moriarty, N.W., Read, R.J., Sacchettini, J.C., Sauter, N.K., and
Terwilliger, T.C. (2002). PHENIX: building new software for automated crys-Structure 23, 1382tallographic structure determination. Acta Crystallogr. D Biol. Crystallogr.
58, 1948–1954.
Aramini, J.M., Hamilton, K., Ma, L.C., Swapna, G.V., Leonard, P.G., Ladbury,
J.E., Krug, R.M., andMontelione, G.T. (2014). 19F NMR revealsmultiple confor-
mations at the dimer interface of the nonstructural protein 1 effector domain
from influenza A virus. Structure 22, 515–525.
Ashkenazy, H., Erez, E., Martz, E., Pupko, T., and Ben-Tal, N. (2010). ConSurf
2010: calculating evolutionary conservation in sequence and structure of
proteins and nucleic acids. Nucleic Acids Res. 38, W529–W533.
Bahrami, A., Assadi, A.H., Markley, J.L., and Eghbalnia, H.R. (2009).
Probabilistic interaction network of evidence algorithm and its application to
complete labeling of peak lists from protein NMR spectroscopy. PLoS
Comput. Biol. 5, e1000307.
Bai, Y., Milne, J.S., Mayne, L., and Englander, S.W. (1993). Primary structure
effects on peptide group hydrogen exchange. Proteins 17, 75–86.
Bhattacharya, A., Tejero, R., and Montelione, G.T. (2007). Evaluating protein
structures determined by structural genomics consortia. Proteins 66, 778–795.
Boehr, D.D., Nussinov, R., and Wright, P.E. (2009). The role of dynamic
conformational ensembles in biomolecular recognition. Nat. Chem. Biol. 5,
789–796.
Bru¨nger, A.T., Adams, P.D., Clore, G.M., DeLano, W.L., Gros, P., Grosse-
Kunstleve, R.W., Jiang, J.S., Kuszewski, J., Nilges, M., Pannu, N.S., et al.
(1998). Crystallography & NMR system: A new software suite for macromolec-
ular structure determination. Acta Crystallogr. D Biol. Crystallogr. 54, 905–921.
Chayen, N.E., Stewart, P.D.S., Maeder, D.L., and Blow, D.M. (1990). An auto-
mated-system for microbatch protein crystallization and screening. J. Appl.
Crystallogr. 23, 297–302.
Davis, I.W., Leaver-Fay, A., Chen, V.B., Block, J.N., Kapral, G.J., Wang, X.,
Murray, L.W., Arendall, W.B., 3rd, Snoeyink, J., Richardson, J.S., and
Richardson, D.C. (2007). MolProbity: all-atom contacts and structure valida-
tion for proteins and nucleic acids. Nucleic Acids Res. 35, W375–W383.
Delaglio, F., Grzesiek, S., Vuister, G.W., Zhu, G., Pfeifer, J., and Bax, A. (1995).
NMRPipe: a multidimensional spectral processing system based on UNIX
pipes. J. Biomol. NMR 6, 277–293.
Doublie, S., Kapp, U., Aberg, A., Brown, K., Strub, K., and Cusack, S. (1996).
Crystallization and preliminary X-ray analysis of the 9 kDa protein of the mouse
signal recognition particle and the selenomethionyl-SRP9. FEBS Lett. 384,
219–221.
El-Nassan, H.B. (2014). Recent progress in the identification of BRAF inhibitors
as anti-cancer agents. Eur. J. Med. Chem. 72, 170–205.
Emerson, S.D., Madison, V.S., Palermo, R.E., Waugh, D.S., Scheffler, J.E.,
Tsao, K.L., Kiefer, S.E., Liu, S.P., and Fry, D.C. (1995). Solution structure of
the Ras-binding domain of c-Raf-1 and identification of its Ras interaction
surface. Biochemistry 34, 6911–6918.
Emsley, P., and Cowtan, K. (2004). Coot: model-building tools for molecular
graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126–2132.
Evena¨s, J., Tugarinov, V., Skrynnikov, N.R., Goto, N.K., Muhandiram, R., and
Kay, L.E. (2001). Ligand-induced structural changes to maltodextrin-binding
protein as studied by solution NMR spectroscopy. J. Mol. Biol. 309, 961–974.
Farrow, N.A., Muhandiram, R., Singer, A.U., Pascal, S.M., Kay, C.M., Gish, G.,
Shoelson, S.E., Pawson, T., Forman-Kay, J.D., and Kay, L.E. (1994). Backbone
dynamics of a free and phosphopeptide-complexed Src homology 2 domain
studied by 15N NMR relaxation. Biochemistry 33, 5984–6003.
Fenwick, R.B., Orellana, L., Esteban-Martin, S., Orozco, M., and Salvatella, X.
(2014). Correlated motions are a fundamental property of b-sheets. Nat.
Commun. 5, 4070.
Fetics, S.K., Guterres, H., Kearney, B.M., Buhrman, G., Ma, B., Nussinov, R.,
and Mattos, C. (2015). Allosteric effects of the oncogenic RasQ61L mutant on
Raf-RBD. Structure 23, 505–516.
Filchtinski, D., Sharabi, O., Ru¨ppel, A., Vetter, I.R., Herrmann, C., and Shifman,
J.M. (2010). What makes Ras an efficient molecular switch: a computational,
biophysical, and structural study of Ras-GDP interactions with mutants of
Raf. J. Mol. Biol. 399, 422–435.–1393, August 4, 2015 ª2015 Elsevier Ltd All rights reserved 1391
Finn, R.D., Bateman, A., Clements, J., Coggill, P., Eberhardt, R.Y., Eddy, S.R.,
Heger, A., Hetherington, K., Holm, L., Mistry, J., et al. (2014). Pfam: the protein
families database. Nucleic Acids Res. 42, D222–D230.
Fischer, A., Hekman, M., Kuhlmann, J., Rubio, I., Wiese, S., and Rapp, U.R.
(2007). B- and C-RAF display essential differences in their binding to Ras:
the isotype-specific N terminus of B-RAF facilitates Ras binding. J. Biol.
Chem. 282, 26503–26516.
Fushman, D., Weisemann, R., Thuring, H., and Ruterjans, H. (1994). Backbone
dynamics of ribonuclease T1 and its complex with 2’GMP studied by two-
dimensional heteronuclear NMR spectroscopy. J. Biomol. NMR 4, 61–78.
Glaser, F., Pupko, T., Paz, I., Bell, R.E., Bechor-Shental, D., Martz, E., and
Ben-Tal, N. (2003). ConSurf: identification of functional regions in proteins by
surface-mapping of phylogenetic information. Bioinformatics 19, 163–164.
Gohlke, H., Kiel, C., and Case, D.A. (2003). Insights into protein-protein binding
by binding free energy calculation and free energy decomposition for the Ras-
Raf and Ras-RalGDS complexes. J. Mol. Biol. 330, 891–913.
Gohlke, H., Kuhn, L.A., and Case, D.A. (2004). Change in protein flexibility
upon complex formation: analysis of Ras-Raf using molecular dynamics and
a molecular framework approach. Proteins 56, 322–337.
Gu¨ntert, P., Mumenthaler, C., andWu¨thrich, K. (1997). Torsion angle dynamics
for NMR structure calculation with the new program DYANA. J. Mol. Biol. 273,
283–298.
Hendrickson, W.A. (1991). Determination of macromolecular structures from
anomalous diffraction of synchrotron radiation. Science 254, 51–58.
Herrmann, T., Gu¨ntert, P., and Wu¨thrich, K. (2002). Protein NMR structure
determination with automated NOE assignment using the new software
CANDID and the torsion angle dynamics algorithm DYANA. J. Mol. Biol. 319,
209–227.
Holm, L., and Rosenstro¨m, P. (2010). Dali server: conservation mapping in 3D.
Nucleic Acids Res. 38, W545–W549.
Huang, Y.J., and Montelione, G.T. (2005). Structural biology: proteins flex to
function. Nature 438, 36–37.
Huang, Y.J., Powers, R., and Montelione, G.T. (2005). Protein NMR recall,
precision, and F-measure scores (RPF scores): structure quality assessment
measures based on information retrieval statistics. J. Am. Chem. Soc. 127,
1665–1674.
Huang, Y.J., Hang, D., Lu, L.J., Tong, L., Gerstein, M.B., and Montelione, G.T.
(2008). Targeting the human cancer pathway protein interaction network by
structural genomics. Mol. Cell Proteomics 7, 2048–2060.
Huang, Y.J., Rosato, A., Singh, G., and Montelione, G.T. (2012). RPF: a quality
assessment tool for protein NMR structures. Nucleic Acids Res. 40, W542–
W546.
Jansson, M., Li, Y.C., Jendeberg, L., Anderson, S., Montelione, G.T., and
Nilsson, B. (1996). High-level production of uniformly 15N- and 13C-enriched
fusion proteins in Escherichia coli. J. Biomol. NMR 7, 131–141.
Kapust, R.B., To¨zse´r, J., Fox, J.D., Anderson, D.E., Cherry, S., Copeland, T.D.,
andWaugh, D.S. (2001). Tobacco etch virus protease: mechanism of autolysis
and rational design of stable mutants with wild-type catalytic proficiency.
Protein Eng. 14, 993–1000.
Kay, L.E., Torchia, D.A., and Bax, A. (1989). Backbone dynamics of proteins as
studied by 15N inverse detected heteronuclear NMR spectroscopy: applica-
tion to staphylococcal nuclease. Biochemistry 28, 8972–8979.
Kitevski-LeBlanc, J.L., and Prosser, R.S. (2012). Current applications of 19F
NMR to studies of protein structure and dynamics. Prog. Nucl. Magn.
Reson. Spectrosc. 62, 1–33.
Kraulis, P.J., Domaille, P.J., Campbell-Burk, S.L., Van Aken, T., and Laue, E.D.
(1994). Solution structure and dynamics of ras p21,GDP determined by heter-
onuclear three- and four-dimensional NMR spectroscopy. Biochemistry 33,
3515–3531.
Krishna, M.M., Hoang, L., Lin, Y., and Englander, S.W. (2004). Hydrogen
exchange methods to study protein folding. Methods 34, 51–64.
Laskowski, R.A., MacArthur, M.W., Moss, D.S., and Thornton, J.M. (1993).
PROCHECK - a program to check the stereochemical quality of protein struc-
tures. J. Appl. Crystallogr. 26, 283–291.1392 Structure 23, 1382–1393, August 4, 2015 ª2015 Elsevier Ltd AlLavoie, H., and Therrien, M. (2015). Regulation of RAF protein kinases in ERK
signalling. Nat. Rev. Mol. Cell Biol 16, 281–298.
Lavoie, H., Li, J.J., Thevakumaran, N., Therrien, M., and Sicheri, F. (2014).
Dimerization-induced allostery in protein kinase regulation. Trends Biochem.
Sci. 39, 475–486.
Linge, J.P., Williams, M.A., Spronk, C.A., Bonvin, A.M., and Nilges, M.
(2003). Refinement of protein structures in explicit solvent. Proteins 50,
496–506.
Manning, G.,Whyte, D.B., Martinez, R., Hunter, T., and Sudarsanam, S. (2002).
The protein kinase complement of the human genome. Science 298, 1912–
1934.
Matallanas, D., Birtwistle, M., Romano, D., Zebisch, A., Rauch, J., von
Kriegsheim, A., and Kolch, W. (2011). Raf family kinases: old dogs have
learned new tricks. Genes Cancer 2, 232–260.
Milburn, M.V., Tong, L., deVos, A.M., Bru¨nger, A., Yamaizumi, Z., Nishimura,
S., and Kim, S.H. (1990). Molecular switch for signal transduction: structural
differences between active and inactive forms of protooncogenic ras proteins.
Science 247, 939–945.
Moseley, H.N., Monleon, D., and Montelione, G.T. (2001). Automatic
determination of protein backbone resonance assignments from triple reso-
nance nuclear magnetic resonance data. Methods Enzymol. 339, 91–108.
Motlagh, H.N., Wrabl, J.O., Li, J., and Hilser, V.J. (2014). The ensemble nature
of allostery. Nature 508, 331–339.
Nassar, N., Horn, G., Herrmann, C., Scherer, A., McCormick, F., and
Wittinghofer, A. (1995). The 2.2 A˚ crystal structure of the Ras-binding domain
of the serine/threonine kinase c-Raf1 in complex with Rap1A and a GTP
analogue. Nature 375, 554–560.
Otwinowski, Z., and Minor, W. (1997). Processing of X-ray diffraction data
collected in oscillation mode. Methods Enzymol. 276, 307–326.
Robert, X., and Gouet, P. (2014). Deciphering key features in protein structures
with the new ENDscript server. Nucleic Acids Res. 42, W320–W324.
Roskoski, R., Jr. (2010). RAF protein-serine/threonine kinases: structure and
regulation. Biochem. Biophys. Res. Commun. 399, 313–317.
Rosnizeck, I.C., Filchtinski, D., Lopes, R.P., Kieninger, B., Herrmann, C.,
Kalbitzer, H.R., and Spoerner, M. (2014). Elucidating the mode of action of a
typical Ras state 1(T) inhibitor. Biochemistry 53, 3867–3878.
Schanda, P., and Brutscher, B. (2005). Very fast two-dimensional NMR
spectroscopy for real-time investigation of dynamic events in proteins on the
time scale of seconds. J. Am. Chem. Soc. 127, 8014–8015.
Schneider, T.R., and Sheldrick, G.M. (2002). Substructure solution with
SHELXD. Acta Crystallogr. D Biol. Crystallogr. 58, 1772–1779.
Sekhar, A., and Kay, L.E. (2013). NMR paves the way for atomic level descrip-
tions of sparsely populated, transiently formed biomolecular conformers.
Proc. Natl. Acad. Sci. USA 110, 12867–12874.
Shen, Y., Delaglio, F., Cornilescu, G., and Bax, A. (2009). TALOS+: a hybrid
method for predicting protein backbone torsion angles from NMR chemical
shifts. J. Biomol. NMR 44, 213–223.
Sievers, F., Wilm, A., Dineen, D., Gibson, T.J., Karplus, K., Li, W., Lopez, R.,
McWilliam, H., Remmert, M., So¨ding, J., et al. (2011). Fast, scalable generation
of high-quality protein multiple sequence alignments using Clustal Omega.
Mol. Syst. Biol. 7, 539.
Smith, S.J., and Rittinger, K. (2002). Preparation of GTPases for structural and
biophysical analysis. Methods Mol. Biol. 189, 13–24.
Smith, M.J., and Ikura, M. (2014). Integrated RAS signaling defined by par-
allel NMR detection of effectors and regulators. Nat. Chem. Biol. 10,
223–230.
Smith, M.J., Neel, B.G., and Ikura, M. (2013). NMR-based functional profiling
of RASopathies and oncogenic RAS mutations. Proc. Natl. Acad. Sci. USA
110, 4574–4579.
Spoerner, M., Wittinghofer, A., and Kalbitzer, H.R. (2004). Perturbation of
the conformational equilibria in Ras by selective mutations as studied by 31P
NMR spectroscopy. FEBS Lett. 578, 305–310.l rights reserved
Spoerner, M., Nuehs, A., Ganser, P., Herrmann, C., Wittinghofer, A., and
Kalbitzer, H.R. (2005). Conformational states of Ras complexed with the
GTP analogue GppNHp or GppCH2p: implications for the interaction with
effector proteins. Biochemistry 44, 2225–2236.
Spoerner, M., Hozsa, C., Poetzl, J.A., Reiss, K., Ganser, P., Geyer, M., and
Kalbitzer, H.R. (2010). Conformational states of human rat sarcoma (Ras) pro-
tein complexed with its natural ligand GTP and their role for effector interaction
and GTP hydrolysis. J. Biol. Chem. 285, 39768–39778.
Stephen, A.G., Esposito, D., Bagni, R.K., and McCormick, F. (2014). Dragging
Ras back in the ring. Cancer Cell 25, 272–281.
Takai, Y., Sasaki, T., and Matozaki, T. (2001). Small GTP-binding proteins.
Physiol. Rev. 81, 153–208.
Terada, T., Ito, Y., Shirouzu, M., Tateno, M., Hashimoto, K., Kigawa, T.,
Ebisuzaki, T., Takio, K., Shibata, T., Yokoyama, S., et al. (1999). Nuclear
magnetic resonance and molecular dynamics studies on the interactions ofStructure 23, 1382the Ras-binding domain of Raf-1 with wild-type and mutant Ras proteins.
J. Mol. Biol. 286, 219–232.
Thevakumaran, N., Lavoie, H., Critton, D.A., Tebben, A., Marinier, A., Sicheri,
F., and Therrien, M. (2015). Crystal structure of a BRAF kinase domain mono-
mer explains basis for allosteric regulation. Nat. Struct. Mol. Biol. 22, 37–43.
Tzeng, S.R., and Kalodimos, C.G. (2011). Protein dynamics and allostery: an
NMR view. Curr. Opin. Struct. Biol. 21, 62–67.
Tzeng, S.R., and Kalodimos, C.G. (2012). Protein activity regulation by confor-
mational entropy. Nature 488, 236–240.
Wand, A.J. (2013). The dark energy of proteins comes to light: conformational
entropy and its role in protein function revealed by NMR relaxation. Curr. Opin.
Struct. Biol. 23, 75–81.
Yu, J.X., Hallac, R.R., Chiguru, S., and Mason, R.P. (2013). New frontiers
and developing applications in 19F NMR. Prog. Nucl. Magn. Reson.
Spectrosc. 70, 25–49.–1393, August 4, 2015 ª2015 Elsevier Ltd All rights reserved 1393
